The AIM Index has posted some modest gains on Wednesday but continues to lag behind both the main board and the pace across the Atlantic. Risk appetite may be returning but it still seems pretty limited.
- Celadon Pharma +19%
- Xtract Resources +15%
- KCR Residential +15%
- Biodexa Pharma -31%
- Versarien -16%
Celadon Pharma LON:CEL topped the board in what was a muted session, adding 19% by the bell. The medical cannabis company updated the market a couple of weeks back in response to a Home Office license approval but there appear to be some who believe the upside hasn’t been fully priced in yet.
Xtract Resources LON:XTR advanced 15% with meaningfully elevated volumes across a limited number of trades. It helps recover some of the recent losses but the move was only just beyond the quoted spread.
KCR Residential LON:KCR advanced 15% off the back of its half year report this morning. The business continues to grow despite well reported headwinds, with revenues up some 30%.
Biodexa Pharma [LON:BDRX] was 31% lower, propping up the table at the bell. The company was recently renamed from Midatech Pharma but this morning announced an issue of new equity.
- AIM Market Roundup: Fiinu, Celadon, Cambridge Nutritional
- Three Quick Facts: Tullow, Chapel Down, Versarien
- Small Cap Stocks: Vela Technologies, Caspian Sun, Nostra Terra
Versarien LON:VRS slipped 16% after advising the market ahead of its AGM that further funding was required to support operations. All resolutions at the AGM were passed but the prospect of a capital raise is clearly weighing.